Last edition
News about "Acepodia "
Acepodia Doses First Patient in Phase 1 Trial of ACE723 for Liver Cancer
Acepodia has dosed the first patient in its Phase 1 clinical trial of ACE723, an investigational dual-payload ADC for unresectable or metastatic hepatocellular carcinoma.
Acepodia | 06/11/2026 | By News Bureau
Acepodia Receives FDA Clearance for ACE723 ADC in Advanced Liver Cancer
Acepodia’s ACE723 is designed to deliver two cytotoxic payloads to GPC3-expressing tumour cells in patients with unresectable or metastatic hepatocellular carcinoma.
Acepodia | 07/09/2026 | By News Bureau | 138
Acepodia Signs Strategic Clinical Partnership with Pfizer for Autoimmune Diseases
Under this new agreement, Pfizer Ignite will provide strategic guidance and resources to Acepodia as the company develops its cell therapies for oncology and autoimmune diseases.
Acepodia | 04/09/2024 | By Aishwarya | 397
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy